Vectus Biosystems Limited
Vectus Biosystems Limited (VBS.AX) Stock Overview
Explore Vectus Biosystems Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2M
P/E Ratio
-0.87
EPS (TTM)
$-0.04
ROE
-2.39%
VBS.AX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Vectus Biosystems Limited (VBS.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 24.72, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $0.08.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.87 and a market capitalization of 2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
Ivan Rajkovic
3-11 Primrose Avenue, Rosebery, NSW
2016